SenoReverse™ is a proprietary miRNA platform that restores the proliferative capacity of senescent cells, in programs spanning therapeutics and consumer healthcare.
One mechanism and one chemistry across skin, neurodegeneration, and age-related fibrotic and metabolic disease.
Lifespan study in aged mice, dosed from month 20 until natural death; n = 80.
Two lead indications: sarcopenia and androgenetic alopecia.
SenoReverse™ acts on senescence- and cell-cycle-related targets, releasing senescent cells from proliferative arrest and restoring their function while the tissue retains its cells. Clearance reduces the tissue's total cell population; reversal leaves it intact.
A second, epigenetic arm of the mechanism has been characterized in neuronal models, operating in parallel with the cell-cycle arm. One chemistry supports eight indications across skin, neurodegeneration, and age-related fibrotic and metabolic disease.
Represses senescence- and cell-cycle-related targets.
Senescent cells exit proliferative arrest and re-enter the cell cycle.
Tissue regenerative capacity is restored, and SASP signaling declines.
First-in-human dosing was completed in 2026, with an IND submission for sarcopenia and androgenetic alopecia planned for 2027.
Pharmacodynamic, pharmacokinetic, and toxicology studies in aged rats are complete. Complement-activation and PBMC safety assays were both negative, and the drug-substance process has been finalized.
A dose-ranging and pharmacokinetic study in non-human primates is underway: subcutaneous administration, three dose levels, and serial muscle biopsies at four time points.
First-in-human dosing was completed in 2026, followed by an IND submission in 2027.
A skin-directed nucleic-acid product line for skin quality and appearance, supplied as a two-part lyophilized formulation with device-assisted dermal delivery. The product line is registered, and commercial rollout is underway.
Market registration completed.
Commercial rollout underway across multiple channels.
An independent third-party laboratory substantiated firming and anti-wrinkle efficacy in instrument-graded human studies; 84 subjects completed the studies and no adverse reactions were reported.
Reversal, not clearance.
Senovance restores the function of senescent cells, and the tissue retains them.
Senovance is an age-related disease biotechnology company built on SenoReverse™, a proprietary miRNA platform that reverses senescent cell-cycle arrest.
The company is backed by institutional venture investors. Its founding team combines internationally recognized scientists in aging biology with senior pharmaceutical clinical-development executives, and works with two academic clinical centers.